| Home | E-Submission | Sitemap | Contact Us |  
Korean J Intern Med > Volume 33(2); 2018 > Article
Cha, Min, Kim, Lee, Lee, Kim, Song, Cha, and Kang: Long-term study of the association of adipokines and glucose variability with diabetic complications



Recent studies have suggested an important role of adipokines in the development of insulin resistance and diabetes mellitus. The clinical relevance of adipokines on long-term outcomes in patients with diabetes and chronic kidney disease is uncertain. The purpose of this study was to identify a predictable factor in patients with long-term diabetic complications.


A total of 161 diabetic individuals were followed-up from 2002 to 2013. Circulating plasma levels of adiponectin, glypican-4, irisin, visfatin, and visit-to-visit glucose variability were measured in diabetic patients. Associations among adipokines and variable metabolic parameters and microvascular, and macrovascular complications were evaluated.


Plasma adiponectin and glypican-4 levels were significantly increased in patients with renal insufficiency. These adipokines were negatively associated with estimated glomerular filtration rate and positively associated with urinary albumin excretion. The relative risk of renal progression to dialysis increased independently with increasing level of adiponectin. Glypican-4 and visfatin were not predictive of any microvascular or macrovascular complications. Glucose variability increased the risk of diabetic nephropathy and cerebrovascular complications.


Adiponectin and glypican-4 were associated with renal function and might be able to predict renal progression. Glucose variability was a predictable factor for diabetic nephropathy and cerebrovascular complications.


The growing prevalence of diabetes mellitus (DM) is a global health problem, leading cause of chronic kidney disease (CKD) and cardiovascular diseases. Various treatments have reduced acute complications of DM. Optimized control of blood glucose improved life expectancy and lowered the risk of death in diabetic patients. However, more patients have been suffering from long-term diabetic complications such as renal disease despite remarkable progress in improving therapy. Therefore, novel predictable factors are needed to prevent different disease pathways of diabetic complications. Recent studies have demonstrated that increased levels of proinflammatory cytokines, chemokines, and oxidative stress are associated with all types of DM, suggesting an inflammatory component in the pathogenesis of DM [1,2]. For many years, adipose tissue was largely regarded as a tissue of nutrient storage; however, it is now recognized as a secretory organ that generates various bioactive proteins referred to as adipokines [3]. Importantly, adipokines act in a similar manner as classic cytokines and chemokines, regulating insulin sensitivity and immune responses to modulate physiological metabolic and inflammatory processes. Adipokines can act both locally within adipose tissue as well as systemically via secretion into circulation. Specifically, adipokines released in the circulation are thought to interact with other organs such as the cardiovascular system, central nervous system, liver, pancreas, skeletal muscles, and kidney [4]. Previous studies have reported altered levels of adipokines in patients with renal dysfunction [5,6]. In addition, experimental studies have revealed the influence of certain types of adipokines on kidney injury via regulation of endothelial dysfunction, oxidative stress, and inflammatory processes [7,8].
Of adipokines, leptin and adiponectin have been studied a lot in diabetic complications. However, the roles of many adipokines including retinol binding protein 4, resistin, hepcidin, visfatin, and glypican-4, all of which are primarily secreted by white adipose tissues, are not clear in terms of association with diabetic complications [9]. Although the exact roles of each of these different adipokines are not fully understood, clinical and experimental studies have suggested that several adipokines have protective effects against progression of metabolic and inflammatory disorders. We focused on new emerging adipokines of glypican-4, irisin, and visfatin as protective predictors in long-term diabetic complications. Leptin has been a well known adipokine, but was omitted in this study because we have already reported the association of plasma leptin level with diabetic nephropathy [10]. Adiponectin, as another well-known adipokine, was analysed in this study.
The majority of previous studies performed in diabetic patients have reported cross-sectional associations of adipokines with renal and metabolic parameters. Studies to investigate the association of adipokines with long-term outcome in DM have been rare. Therefore, in the present study, we examined the association of adipokines with renal dysfunction and metabolic parameters in diabetic patients and also investigated the relationship of adipokine levels with long-term diabetic complications over an 11 years follow-up period.



This study was a prospective observational study on adipokine levels and metabolic parameters in patients with diabetic kidney disease. A total of 295 diabetic patients were enrolled to the study from Korea University Ansan Hospital and 161 patients had been followed from 2002 to 2013. Forty-five percentage of total patients were droped out due to death, transfer, and withdrawal after 11 years. The protocols and procedures of study were conducted with approval by the Korea University Ansan Hospital Institutional Review Board (AS15152-001) and were conducted according to the principles expressed in the Declaration of Helsinki. Data were collected after obtaining written consent from each participant. The diagnosis of DM was based on fasting plasma glucose > 126 mg/dL (7.0 mmol) and/or random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) according to the World Health Organization 1998 diagnostic criteria [11], although criteria for the diagnosis of diabetes have been updated after the enrollment of patients [12]. The presence of diabetic nephropathy was screened by standard methods according to the definition by the American Diabetes Association [13]. CKD was defined as abnormality of kidney structure or function, present for more than 3 months with implication for health according to the guidelines introduced by the National Kidney Foundation and Kidney Disease Outcomes Quality Initiative. Patients were categorized into three groups according to renal function (estimated glomerular filtration rate [eGFR]) as follows: eGFR ≥ 60 mL/min/1.73 m2, 30 ≤ eGFR < 60 mL/min/1.73 m2, and eGFR < 30 mL/min/1.73 m2).
Patient medical histories were reviewed using medical charts, and exclusion criteria were as follows: (1) younger than 18 years of age or older than 80; (2) acute illness including acute inflammatory event or cardiovascular or cerebrovascular event within 3 months; (3) chronic liver disease; and (4) malignancy. Demographic data including age, gender, history of hypertension, cardiovascular disease, cerebrovascular disease, smoking history, and prescribed medications were obtained from patient medical charts. Body weight, height, and blood pressure were measured at the time of the clinic visit.

Anthropometric measurements

Blood samples for biochemical measurements were collected at the time of study enrollment. The following variables were measured: complete blood count (hemoglobin, white blood cell count, platelets) and serum sodium, potassium, chloride, creatinine, and lipid profiles (total cholesterol, low density lipoprotein cholesterol [LDL-C], high density lipoprotein cholesterol [HDL-C], and triglycerides). Fasting plasma glucose and fasting blood glucose were measured using glucometers at every clinic visit. Glucose variability was calculated using 3 to 6 months interval visit-to-visit variability. Standard deviations (SDs) of fasting glucose and coefficient of variance (CV) were used as indices of glucose variability. The CV (%) was calculated by expressing the SD as percentage of the mean (CV % = SD/mean × 100). Urine samples were collected for measurement of protein, albumin, and creatinine excretion. Urine albumin to creatinine ratio (UACR) and urine protein to creatinine ratio (UPCR) were used for analysis. eGFR was calculated using the CKD Epidemiology Collaboration (CKD-EPI) equation: eGFR = 141 × min (SCr/κ, 1)α × max (SCr/κ, 1)−1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where κ is 0.7 for females and 0.9 for males, and α is −0.329 and −0.411, respectively.

Measurement of plasma adipokines levels

The levels of the different adipokines were measured using commercially available kits, and all samples were measured in duplicate. Specifically, adiponectin was measured using an enzyme immunoassay technique (ALPCO Diagnostic Inc., Salem, NH, USA), which had intra-assay and interassay CVs of 4.5% and 5.0%, respectively. Glypican-4 was assayed using enzyme-linked immunosorbent assay (MyBioSource Inc., San Diego, CA, USA), and the corresponding intra-assay and interassay CVs were < 8% and < 10%, respectively. Levels of irisin and visfatin were assayed using EIA kits (Phoenix Pharmaceuticals, Burlingame, CA, USA), and the intra-assay and interassay CVs were < 10% and < 15% for irisin and < 5% for visfatin, respectively. For visfatin, only 99 of 161 patients participated.

Microvascular and macrovascular diabetic complications

In this study, the presence and development of diabetic complications were examined during an approximate follow-up period of 11 years. Renal complications were considered as presence of microalbuminuria, overt proteinuria, and progression to CKD with dialysis. Retinopathy development was examined by an ophthalmologist, while peripheral neuropathy was examined by a neurologist using an electromyogram. Cardiovascular and cerebrovascular disease complications were defined as development of myocardial infarction, angina, coronary revascularization, heart failure, cerebrovascular infarction, or hemorrhage.

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics version 20 (IBM Co., Armonk, NY, USA). Censored data included data from patients who were loss during the follow-up period due to transfer to local clinics, withdrawal and deaths. Values of p < 0.05 were considered statistically significant. Data were expressed as mean ± SD and percentage for categorical variables. Continuous variable analysis between two groups was performed using a 2-sample t test or Mann-Whitney U test. Analysis among more than three groups was performed using one-way analysis of variance with Tukey B test or Games-Howell test and Kruskal-Wallis test for nonparametric samples. Categorical data analysis was determined using Pearson chi-square test. Univariate and multivariate linear regression analyses with a stepwise selection method were used to evaluate correlations of adipokines with metabolic parameters. For variables with a skewed deviation, logarithmic transformations were applied. The standard distributions of each variable were examined using one sample Kolmogorov-Smirnov test. p value of each adipokines were as follows; adiponectin (log) (p = 0.837), irisin (log) (p = 0.137), glypican-4 (p = 0.059), visfatin (p = 0.945). Binary logistic regression model was employed to estimate the odds ratio (OR) and 95% confidence interval (CI) of adipokines for predicting diabetic complications. Variables with p < 0.05 from univariate binary logistic regression analysis were retained and evaluated for further multivariate logistic regression analysis model. Forward Wald selection method was performed.


Baseline demographic and clinical characteristics

Participants were all recruited from a single medical center. Baseline demographic and laboratory characteristics are shown in Table 1. A total of 161 patients were followed up from 2002 to 2013. All of the study participants were Asian and had a mean age of 53.9 ± 12.01 years and mean DM duration of 8.3 ± 7.81 years. Of the total patients, 14 (8.6%) were diagnosed as having type 1 DM. Patients with an eGFR between 30 to 60 mL/min/1.73 m2 were older and had a longer duration of diabetes, while patients with renal insufficiency (< 60 mL/min/1.73 m2) exhibited significantly higher systolic blood pressure (SBP) and were more likely to have history of hypertension and use of anti-hypertensive medications, insulin, or statins. Urine albumin and protein excretion was considerably increased in patients with severe renal insufficiency (< 30 mL/min/1.73 m2). Serum cholesterol levels were not significantly different among the groups, but there was a trend toward increased levels in patients with renal insufficiency. The differences in body mass index (BMI, kg/m2), fasting plasma and glycated hemoglobin (HbA1c) between the groups were not significant.

Plasma circulating levels of adipokines and glucose variability among the groups

As shown in Fig 1, circulating plasma adipokines were compared among three groups depending on renal function. Plasma adiponectin level was significantly higher in patients with renal insufficiency with eGFR below 30 mL/min/1.73 m2. Plasma glypican-4 level was also significantly higher in patients with renal insufficiency with eGFR below 30 mL/min/1.73 m2. Plasma irisin level trended lower in patients with renal insufficiency. Plasma visfatin level was not changed among three groups. Although there was no change in glucose variability (SD) among three groups, we observed the CV (%) was higher in in patients with renal insufficiency with eGFR below 60 mL/min/1.73 m2.

Univariate linear analysis of adipokines with clinical and metabolic parameters

Linear associations of each adipokine with renal and metabolic parameters are described in Table 2. Linear regression analysis revealed a significant negative association of adiponectin with eGFR but a positive association with UACR. Adiponectin was positively associated with age, duration of diabetes, serum cholesterol (total, LDL-C, and HDL-C) levels, and use of calcium channel blockers. Females had higher levels of adiponectin compared to males. Plasma glypican-4 level was significantly higher in patients with renal insufficiency and was inversely associated with eGFR in a similar manner to adiponectin. Additionally, glypican-4 level was positively correlated with UACR, serum LDL-C level, and use of angiotensin converting enzyme (ACE) inhibitors and negatively correlated with glucose variability. Irisin level exhibited a decreasing trend in patients with renal insufficiency, although there was no significant linear association with eGFR. A significant association was noted between levels of irisin and SBP and use of sulfonylurea. Visfatin was not significantly different among groups, nor did it show any significant association with other metabolic parameters.

Multivariate regression analysis of adipokines with clinical and metabolic parameters

When fully adjusted for relevant parameters as shown in Table 3, age, total cholesterol and HDL-C was significantly correlated with plasma adiponectin level. Multivariate linear regression analysis revealed an independent correlation of use of ACE inhibitors with glypican-4 level. Specifically, patients who used sulfonylurea exhibited decreased level of irisin. Lastly, visit-to-visit glucose variability was examined to evaluate glucose fluctuation during the study period. Percentage of CV, an index of glucose variability, was significantly increased in patients with renal insufficiency, but was not significantly correlated with any of the adipokines evaluated.

Prevalence of renal complications and relative risks for renal complications

Prevalence of diabetic complications at the time of enrollment and at the end of the study is shown in Table 4. Between 2002 and 2013, there were an increased number of diabetic complications, with more than half of the patients reporting diabetic nephropathy. As expected, patients with low eGFR and high UACR and UPCR were more likely to have diabetic nephropathy. Likewise, hypertensive patients were at a higher risk of diabetic nephropathy, as were patients who were on antihypertensive β-blockers and CCB. Interestingly, glucose variability increased the risk of diabetic nephropathy. Neither fasting glucose nor HbA1c was associated with diabetic nephropathy. Furthermore, UACR, glucose variability, and hypertension significantly and independently increased the risk of diabetic nephropathy. Increased plasma adiponectin levels was associated with risk of concurrent diabetic nephropathy at the time of enrollment (crude OR, 1.143; 95% CI, 1.032 to 1.266; p = 0.01). However, there were no significant independent associations of adipokines with presence of diabetic nephropathy at the end of the study. On the other hand, the prevalence of progression to dialysis was significantly increased among patients with higher adiponectin level, even after fully adjusting for correlated variables. In addition, low eGFR and high UACR increased the risk of progression to dialysis. The presence of hypertension, high blood pressure, and use of antihypertensive medication and diuretics also significantly increased the risk of progression to dialysis, similar to diabetic nephropathy. Patients who were younger were at increased risk for dialysis, although the significance of this observation was lost in multivariate logistic regression analysis after adjusting for confounding factors.

Relative risks for microvascular and macrovascular complications

Relative risks for microvascular and macrovascular diabetic complications were also evaluated (Tables 5 and 6). The presence of hypertension and duration of diabetes were significant independent risk factors of both retinopathy and neuropathy. In addition, irisin level was significantly lower in patients with retinopathy at the time of enrollment (p = 0.013). Patients with higher level of irisin exhibited decreased risk of retinopathy, while those with higher level of adiponectin had an increased risk of peripheral neuropathy. However, these associations were not significant when fully adjusted for correlated variables. Fasting plasma glucose level and use of sulfonylurea were independent risk factors of retinopathy. Likewise, individuals with lower GFR, older age, history of hypertension, and longer duration of diabetes were at increased risk of macrovascular complications. Hypertension was a significant and potent risk factor of cardiovascular event, while glucose variability was independently associated with increased risk of cerebrovascular event. However, circulating levels of adipokines were not significantly associated with presence of macrovascular complications in our study.


In the present study, we investigated new emerging adipokines that have been suggested to play a protective role in the progression of diabetic complications. After a long time of 11 years, many of diabetic patients presented its complications in this study. It is interesting that plasma levels of adiponectin and glypican-4 were significantly higher in diabetic patients with renal insufficiency and were inversely associated with eGFR. In addition, we identified significant associations between several of the measured adipokines and UACR. Furthermore, adiponectin levels were an independent risk factor of progression to dialysis. However, irisin and visfatin levels were not associated with renal function or progression of renal disease. With respect to metabolic parameters, adiponectin was positively associated with total and HDL-C. As known, established risk factors such as presence of hypertension and duration of diabetes significantly increased the risk of microvascular and macrovascular diabetic complications, while UACR was an independent risk factor of diabetic nephropathy. Convincingly in this study, glucose variability was the best predictable factor in long-term diabetic complications of diabetic nephropathy and cerebrovascular complications.
Adiponectin has been suggested to have anti-inflammatory, anti-oxidative, and insulin-sensitizing effects on various types of cells, and experimental studies have shown that adiponectin regulates oxidative stress and inflammatory pathways via adenosine monophosphate-activated protein kinase activation in the glomerulus and tubules of the kidney [14]. Despite the protective effects of adiponectin on renal progression, clinical studies have shown that high adiponectin levels in patients with kidney disease predict mortality and progression to end-stage renal disease (ESRD) [15,16]. The findings of the present study were consistent with those of previous studies on adiponectin levels in diabetic patients; whereby, adiponectin levels were negatively correlated with eGFR and positively correlated with UACR, a well-known marker of diabetic nephropathy [17]. Plasma adiponectin level has been reported to be elevated in CKD patients, especially in patients with ESRD before dialysis. The measured high molecular weight adiponectin is the main circulating form and the most active form of adiponectin, and despite the liver is considered as the major site of elimination of the adiponectin, the kidney may also play a role for degradation and elimination [18]. Whether the increase in adiponectin level only reflect impaired adiponectin clearance by the kidney or whether it is a compensatory mechanism has not been clearly elucidated yet. Reduced renal clearance of adiponectin does not fully explain high levels of adiponectin in renal insufficiency. Previous studies on adiponectin suggest that the elevation of adiponectin level is not simply the result of impaired excretion. It should be noted that adiponectin is rapidly cleared in the plasma, and that the renal adiponectin clearance are detected mostly in tubules and appears to be intracellular. Also, in a study with patients of renal insufficiency (n = 48, mean GFR 53.5 ± 24.9 mL/min/1.73 m2), adiponectin level was weakly affected by renal function, but were more influenced by proteinuria and metabolic parameters [19]. In addition, gene and protein expression analysis of human adipose tissue in ESRD have shown that in both diabetic and non-diabetic patients, ESRD state contributed to increased level of adiponectin and adiponectin receptor R1 expressions [20]. Therefore, we can speculate that increased adiponectin levels in renal insufficiency are due to increased adiponectin resistance in spite of increased production of adiponectin; therefore, showing little effect on protecting from progressive renal injury. In this study, the level of adiponectin was an independent risk factor of ESRD, despite adiponectin level was not a risk factor of diabetic nephropathy. Thus, adiponectin resistance at the post-receptor level in a uremic state might, at least in part, explain increased risk of renal progression despite high levels of anti-inflammatory adiponectin [18]. Our results provide that adiponetin might different role depending to renal function of diabetic nephropathy.
Disruption of insulin and hyperglycemia are thought to contribute to the development of peripheral neuropathy. In the present study, use of insulin and duration of diabetes were independently associated with risk of peripheral neuropathy, which might be due to long exposure to a hyperglycemic condition and increased insulin resistance. In addition, we found that high adiponectin levels were associated with increased risk of peripheral neuropathy, but the significance of this association was lost after adjusting for confounding factors. Interestingly, several studies have observed increased levels of adiponectin in patients with diabetic neuropathy, whereas other studies have not observed this phenomenon [21].
Glypican-4 is a novel adipokine and a member of the heparan sulfate proteoglycan family of glypicans that bind to various ligands and can be shed from the cell surface, enabling them to act both locally and systemically. Glypican-4 is thought to be involved in growth and differentiation of adipocytes. Ussar et al. [22] previously found that circulating glypican-4 directly interacts with insulin receptors and enhances insulin signaling. In humans, circulating level of glypican-4 was shown to be significantly decreased under diabetic conditions and was also significantly correlated with measures of obesity (BMI, waist to hip ratio, body fat content) and insulin resistance (homeostasis model assessment of insulin resistance) [22,23]. However, an association of glypican-4 with renal function has not been previously reported. In our study, plasma glypican-4 level was higher in patients with severe renal insufficiency, while glypican-4 was inversely correlated with eGFR and positively correlated with UACR, similar to adiponectin. Interestingly, the first report of glypican-4 in the literature was in the developing brain and kidney, where it was shown to be highly expressed in renal tubular cells [24].
In addition to the effects of glypican-4 on adipocytes, glypican-4 has been suggested to bind to Wnt3a and Wnt5a in order to regulate Wnt signaling in cardiomyocytes [25]. Considering the link of insulin signaling and Wnt/β-catenin signaling with progression of diabetic nephropathy, circulating glypican-4 might have an active role on progression of renal complications [26]. Consistent with this possibility, we observed a significant inverse correlation of glypican-4 with glucose variability, indicating that higher glypican-4 level is associated with decreased fluctuation of glycemia. This finding might have been due to the action of glypican-4 in counteracting insulin resistance. Likewise, use of ACE inhibitors was independently and positively associated with glypican-4 regardless of the presence of hypertension, eGFR, or UACR. Currently, there is no data linking ACE inhibitors to glypican-4. Thus, in order to elucidate the role of glypican-4, further experimental and clinical studies exploring the possible action of glypican-4 in the kidney are needed. As for long-term complications, glypican-4 was not predictive of long-term microvascular or macrovascular diabetic complications.
The presence of hypertension and glucose variability significantly increased the risk of diabetic nephropathy. Observational studies in diabetic subjects have shown that visit-to-visit glucose variability in fasting glucose is a risk factor of diabetic complications and mortality [27,28]. Similarly, in vivo fluctuation of glucose in experimental studies has been shown to increase oxidative stress and endothelial injury [29]. Glucose variability reflects fluctuation of glucose levels over the time compared to traditional HbA1c, which level indicates constant exposure of glucose. We speculate that glucose variability is an important measure of poor glycemic control, especially in patients with renal insufficiency, who have reduced clearance of antidiabetic agents and increased insulin resistance. In the present study, glucose variability also increased relative risk of cerebrovascular disease.
Irisin is a newly discovered myokine secreted by myocytes, is proteolytically processed from the product of the fibronectin type III domain containing 5 gene, mediates browning of white adipocytes, and upregulates expression of uncoupling protein-1 level in experimental mice [30]. Recent studies have shown that irisin is also secreted from white adipose tissue and thus has the potential to protect against obesity and insulin resistance [31]. Little is known about the function of irisin in humans, but recent studies have shown that circulating irisin level is significantly lower in obese and diabetic patients, as well as in patients with renal insufficiency [32,33]. In the present study, there was a trend toward decreasing irisin level with advancing stage of kidney disease. However, the range of observed levels of irisin and the corresponding SDs were both very large, which might have weakened the statistical power of our analysis. In addition, irisin level was significantly and positively associated with use of sulfonylurea. While it is not currently clear how irisin correlates with use of sulfonylurea, a previous experimental study with conflicting data showed that metformin but not glibenclamide promotes irisin release from murine skeletal muscle [34]. As there is currently relatively little data on the function of irisin, more research will be necessary to understand the association of sulfonylurea with irisin.
Visfatin is another adipokine that is thought to have insulin mimetic activity [35,36]. In contrast to previous studies on levels of visfatin in patients with diabetes and CKD, we did not identify any changes in visfatin level according to eGFR or UACR. Circulating level of visfatin has been reported to be increased in obesity, type 2 DM, atherothrombotic disease, and CKD. In our study, patients with severe renal insufficiency exhibited relatively increased level of visfatin, but this increase was not statistically significant, which was likely due to the small size of the study.
There were several limitations to the present study. First, the sample size was small, especially for patients with severe renal insufficiency of eGFR < 30 mL/min/1.73 m2. We might have overlooked some associations of adipokines with progression of diabetic complications in patients with severe renal insufficiency, and thus further studies with a larger sample size in a prospective longitudinal study will be needed. Results shown in Tables 4 to 6 were analyzed using binary logistic regression. Our study sample was statistically fit for logistic regression analysis with predictability of more than 90% for each adjusted ORs. To access independent contribution of adiponectin, eGFR was adjusted to exclude the influence of renal function. When divided according to CKD stages (1 to 5), the sample sizes of group 3 to 5 were not sufficiently large to evaluate the independent significance of relevant variables and were not fit for logistic regression analysis (p value for chi-square was more than 0.05). Relative risks of adiponectin for predicting renal complications according to CKD stages are shown in Supplementary Table 1. Second, several adipokines have been suggested to act as bioactive modulators that ameliorate inflammation and oxidative stress and enhance insulin sensitivity. It would be better to compare adipokine levels over 11 years. However, our data did not include the follow-up measurement of adipokine levels and therefore, is not able to characterize the relationship between the final adipokine levels with eGFR at the end of the study, which needs to be evaluated in the future study. Although several studies have shown that therapeutic intervention might change circulating levels of adipokines in certain individuals, we did not consider the impact of medical therapy and life-style modification on levels of adipokines in the present study. Third, both type 1 and type 2 DM patients were enrolled at the time of beginning of the study although only 8.5% of all patients were type 1 DM. Adipokines are generally understood to be associated with metabolic parameters associated with obesity and insulin resistance. In the present study, BMI was not different among groups depending to renal function and not associated with any plasma adipokines. However, BMI alone might not be sufficient to explain the associations of adipokines with obesity [37]. In addition, BMI could not present the body mass precisely due to renal insufficiency and body fluid accumulation in patients with diabetic nephropathy. Although we did not measure the adiposity index of each patient in our study, we compared the gender difference of adiponectin in this study. Gender specific association of adiponectin with the progression of CKD in non-diabetic cohort has been reported by Kollerits et al. [38]. Whereas the baseline adiponectin levels were significant different between men and women in a total population (3.58 ± 2.377 vs. 5.29 ± 4.491, p = 0.002), adiponectin level was predictive for progression to dialysis in women, but not in men in contrast to their study (Supplementary Table 2). It should be taken into consideration that women were aged and had more disturbed metabolic parameters compared to men. At baseline, women group was older, had higher BMI, SBP, and lower eGFR. The differences between the study from Kollerits et al. [38] and ours are that our study population consists of diabetic patients, and there were a wide range of baseline eGFR in the study cohort.
Despite these limitations, our study showed an interesting result to find predictable factors of long-term diabetic complications. The change of adipokine levels might be considered to provide CKD-related inflammatory response rather than obesity-related conditions.
In conclusion, plasma adiponectin and glypican-4 levels are associated with renal function and might be able to predict renal progression in patients with diabetes. Additionally, glucose variability might be a potent risk factor of diabetic nephropathy and cerebrovascular disease. Further clinical and experimental studies with a larger study cohort will be needed to determine the cause and effect relationship between adipokines and diabetic complications.


1. This is the prospective observational study to find predictable factors in long-term diabetic complications.
2. Plasma adiponectin and glypican-4 levels are associated with renal function and might be able to predict renal progression in diabetic patients.
3. Glucose variability might be a potent risk factor of diabetic nephropathy and cerebrovascular diseases.

Conflict of interest

No potential conflict of interest relevant to this article was reported.


This study was supported from Korea University Grant.

Supplementary Materials

Supplementary Table 1.
Relative risks of adiponectin for predicting renal complications according to CKD stages (1 and 2)
Supplementary Table 2.
Gender difference in adiponectin levels on the renal progression in diabetic patients

Figure 1.
Plasma circulating levels of adipokines and glucose variability among the groups in study cohort. (A) Plasma adiponectin level, (B) plasma glypican-4 level, (C) plasma irisin level, (D) plasma visfatin level, (E) standard deviation (SD) values of fasting glucose variability, and (F) % of coefficient variance (CV) of glucose variability. Data are expressed as mean ± SD. eGFR, estimated glomerular filtration rate; NS, not significant.
Table 1.
Demographic and clinical characteristics of study cohort (total, n = 161)
Characteristic eGFR, mL/min/1.73 m2
p value
≥ 60 (n = 120) 30 ≤ and < 60 (n = 32) ≤ 30 (n = 9)
Age, yr 51.7 ± 11.34a 62.9 ± 7.86 49.7 ± 17.7b < 0.001
Sex, male/female 46/74 5/27 1/8
Duration of DM, yr 7.0 ± 7.13 12.5 ± 8.85 10.9 ± 7.59 < 0.001
Type 1 diabetes 11 0 3 0.007
BMI, kg/m2 25.6 ± 3.12 26.4 ± 4.62 24.9 ± 3.23 0.420
SBP, mmHg 128.3 ± 16.01 136.1 ± 16.9 136.7 ± 16.4 0.031
DBP, mmHg 75.5 ± 12.27 73.0 ± 11.11 76.4 ± 10.84 0.558
Hemoglobin, g/dL 13.4 ± 1.43 12.9 ± 1.68 12.7 ± 3.03 0.226
WBC, × 10/μL 6.2 ± 1.97 6.7 ± 1.43 5.8 ± 1.25 0.279
Platelet, × 103/μL 271.0 ± 71.93 258.4 ± 72.37 252.9 ± 79.45 0.615
Sodium, mmol/L 140.7 ± 3.05 141.0 ± 1.91 140.2 ± 3.70 0.814
Potassium, mmol/L 4.3 ± 0.42 4.5 ± 0.40 4.3 ± 0.67 0.230
Cholesterol, mg/dL 193.0 ± 36.70b 202.2 ± 44.03b,c 224.6 ± 67.58c 0.056
LDL-C, mg/dL 106.5 ± 29.42b 104.7 ± 28.89b 140.5 ± 61.27 0.095
Triglyceride, mg/dL 172.1 ± 146.39 180.6 ± 93.17 221.3 ± 152.62 0.581
HDL-C, mg/dL 47.4 ± 12.4 48.2 ± 21.96 42.4 ± 14.16 0.584
FPG, mg/dL 137.8 ± 45.25 149.3 ± 62.41 117.5 ± 79.30 0.236
HbA1c, % 7.7 ± 1.63 7.5 ± 1.65 7.2 ± 0.81 0.647
Creatinine, mg/dL 0.84 ± 0.203 1.29 ± 0.219 4.64 ± 3.136 < 0.001
eGFR, mL/min/1.73 m2 88.9 ± 18.04 47.6 ± 8.52 15.9 ± 8.55 < 0.001
UACR, μg/mg 51.41 ± 232.306b 257.76 ± 787.093b 696.00 ± 1,747.998 0.003
UPCR, mg/mg 0.15 ± 0.362b 0.66 ± 1.913b 7.73 ± 12.140 < 0.001
History of
 Hypertension 39 (32) 19 (59) 8 (89) < 0.001
 Cardiovascular disease 3 (2.5) 4 (13) 7 (77) 0.013
 Cerebrovascular disease 0 2 (6) 5 (56) 0.706
 Retinopathy 40 (33) 19 (59) 7 (77) 0.002
 Neuropathy 31 (26) 12 (38) 5 (56) 0.056
 Smoking 45 (38) 8 (25) 2 (22) 0.228
 ACE inhibitor 23 (19) 7 (22) 5 (56) 0.038
 ARB 23 (19) 16 (50) 3 (33) 0.002
 β-Blocker 5 (4) 3 (9) 5 (56) < 0.001
 Calcium channel blocker 24 (20) 13 (40) 6 (67) 0.001
 Diuretics 1 (0.8) 3 (9) 2 (22) 0.001
 Metformin 61 (51) 13 (41) 3 (33) 0.395
 Sulfonylurea 37 (31) 10 (31) 1 (11) 0.450
 Thiazolidinedione 9 (8) 1 (3) 1 (11) 0.596
 α-Glucosidase inhibitor 21 (18) 4 (13) 3 (33) 0.345
 Insulin 21 (18) 7 (22) 6 (67) 0.002
 Statin 25 (21) 12 (38) 4 (44) 0.064

Values are presented as mean ± SD or number (%).

eGFR, estimated glomerular filtration rate; DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cells; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; UACR, urine albumin to creatinine ratio; UPCR, urine protein to creatinine ratio; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker.

Same letters (a,b,c) indicate non-significant difference between the groups based on Tukey B post hoc analysis.

a Non-significant difference between the group eGFR ≥ 60 vs. group ≤ 30.

b Non-significant difference between the group eGFR ≥ 60 vs. group 30 ≤ and < 60.

c Non-significant difference between the group eGFR 30 ≤ and < 60 vs. group ≤ 30.

Table 2.
Univariate linear analysis of adipokines with clinical and metabolic parameters in study cohort
Variable B ± SE β p value
Adiponectin (log10)
 Age 0.009 ± 0.002 0.354 < 0.001
 Duration of DM 0.011 ± 0.003 0.277 < 0.001
 Body mass index –0.005 ± 0.007 –0.062 0.437
 eGFR –0.004 ± 0.001 –0.342 < 0.001
 Total cholesterol 0.002 ± 0.001 0.226 0.004
 LDL-C 0.003 ± 0.001 0.272 0.007
 HDL-C 0.006 ± 0.002 0.314 < 0.001
 UACR 0.00011 ± 0.000043 0.212 0.010
 UPCR 0.016 ± 0.008 0.184 0.050
 HbA1c –0.006 ± 0.016 –0.031 0.715
 Glucose variability, SDa 0.001 ± 0.001 0.067 0.420
 Use of CCB 0.118 ± 0.053 0.174 0.027
 Male sex –0.138 ± 0.049 –0.216 0.006
 Age –0.027 ± 0.138 –0.016 0.843
 Duration of DM –0.160 ± 0.210 –0.060 0.448
 Body mass index –0.103 ± 0.484 –0.017 0.831
 eGFR –0.119 ± 0.060 –0.156 0.048
 Total cholesterol –0.009 ± 0.041 –0.081 0.818
 LDL-C 0.141 ± 0.065 0.218 0.032
 HDL-C –0.109 ± 0.112 –0.078 0.334
 UACR 0.006 ± 0.003 0.167 0.042
 UPCR 0.324 ± 0.556 0.055 0.562
 HbA1c –0.034 ± 1.107 –0.031 0.975
 Glucose variability, SDa –0.183 ± 0.090 –0.166 0.043
 Use of ACE inhibitor 8.256 ± 3.965 0.163 0.039
Irisin (log10)
 Age 0.002 ± 0.008 0.015 0.853
 Duration of DM 0.006 ± 0.013 0.040 0.615
 Body mass index 0.035 ± 0.028 0.099 0.214
 eGFR –0.001 ± 0.004 –0.015 0.854
 Total cholesterol 0.003 ± 0.002 0.096 0.231
 LDL-C 0.005 ± 0.004 0.152 0.137
 HDL-C –0.008 ± 0.007 –0.096 0.233
 UACR –0.000004 ± 0.00018 –0.020 0.812
 UPCR –0.031 ± 0.030 –0.095 0.317
 HbA1c 0.038 ± 0.068 0.048 0.578
 Glucose variability, SDa –0.002 ± 0.006 –0.032 0.700
 SBP 0.012 ± 0.006 0.161 0.049
 Use of sulfonylurea –0.594 ± 0.209 –0.220 0.005
 Age –0.001 ± 0.002 –0.071 0.483
 Duration of DM –0.001 ± 0.003 –0.037 0.718
 Body mass index 0.003 ± 0.006 0.054 0.601
 eGFR –0.000476 ± 0.00073 –0.065 0.520
 Total cholesterol –0.000017 ± 0.00045 –0.004 0.970
 LDL-C –0.001 ± 0.001 –0.103 0.445
 HDL-C 0.00021 ± 0.00120 0.018 0.858
 UACR –0.0000084 ± 0.000029 –0.030 0.781
 UPCR 0.001 ± 0.012 0.012 0.922
 HbA1c 0.002 ± 0.013 0.013 0.904
 Glucose variability, SDa 0.002 ± 0.001 0.196 0.066

Continuous variables (age, duration of DM, body mass index, eGFR, total cholesterol, LDL-C, HDL-C, UACR, UPCR, SBP), categorical variables (use of CCB, use of ACE inhibitors, use of sulfonylurea).

DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; UACR, urine albumin to creatinine ratio; UPCR, urine protein to creatinine ratio; HbA1c, glycated hemoglobin; SD, standard deviation; CCB, calcium channel blocker; ACE, angiotensin converting enzyme; SBP, systolic blood pressure.

a Standard deviation of visit to visit fasting glucose variability.

Table 3.
Multivariate regression analysis of adipokines with clinical and metabolic parameters in study cohort
Variable B ± SE β p value
Adiponectin (log10)
 Age 0.008 ± 0.002 0.299 0.002a
 Total cholesterol 0.003 ± 0.001 0.341 0.001a
 HDL-C 0.005 ± 0.002 0.297 0.003a
 Use of ACE inhibitor 9.026 ± 4.355 0.212 0.041a
Irisin (log10)
 Use of sulfonylurea –0.720 ± 0.236 –0.255 0.003a

Multivariate analysis for adiponectin; adjusted for age, duration of diabetes mellitus, estimated glomerular filtration rate (eGFR), total cholesterol, low density lipoprotein cholesterol (LDL-C), HDL-C, urine albumin to creatinine ratio (UACR), urine protein to creatinine ratio, glucose variability (standard deviation [SD]), use of calcium channel blocker, and male gender. Multivariate analysis for glypican-4: adjusted for age, eGFR, LDL-C, UACR, glucose variability (SD), and use of ACE inhibitor. Multivariate analysis for irisin (log10): adjusted for age, eGFR, UACR, and systolic blood pressure.

HDL-C, high density lipoprotein cholesterol; ACE, angiotensin converting enzyme.

a Forward selection methods were performed.

Table 4.
Prevalence of diabetic complications at the time of enrollment and relative risks for renal complications in study cohort at the end of the study (11 years follow-up)
Variable Case, n (%) OR 95% CI p value
At the time of enrollment
 Diabetic nephropathy 62 (38.8)
 Retinopathy 66 (40.2)
 Neuropathy 48 (31.2)
 Cardiovascular disease 14 (8.7)
 Cerebrovascular disease 7 (4.3)
At the end of the study
 Diabetic nephropathy 81 (50.6)
  Unadjusted ORs
   Adiponectin, μg/mL 1.092 0.992–1.202 0.071
   Glypican-4, ng/mL 0.999 0.984–1.014 0.859
   Irisin, μg/mL 0.633 0.405–0.989 0.045
   Visfatin, ng/mL 1.283 0.166–9.928 0.812
   eGFR, mL/min/1.73 m2 0.980 0.968–0.992 0.002
   UACR, μg/mg 1.029 1.012–1.045 0.001
   UPCR, mg/mg × 100 1.004 1.001–1.007 0.014
   Glucose variability, CV% 1.066 1.027–1.107 0.001
   SBP, mmHg 1.032 1.010–1.055 0.004
   Hypertension, yes/no 2.755 1.434–5.292 0.002
   Use of insulin, yes/no 3.472 1.500–8.035 0.004
   Use of β-blocker, yes/no 6.050 1.296–28.249 0.022
   Use of CCB, yes/no 2.297 1.112–4.749 0.025
  Adjusted ORs
   UACR, μg/mg 1.034 1.015–1.052 < 0.001
   Glucose variability, CV% 1.065 1.020–1.112 0.005
   Hypertension, yes/no 2.868 1.205–6.826 0.017
 Dialysis 12 (7.5)
  Unadjusted ORs
   Adiponectin, μg/mL 1.249 1.087–1.436 0.002
   Glypican-4, ng/mL 1.021 0.999–1.044 0.057
   Irisin, μg/mL 0.857 0.363–2.019 0.723
   Visfatin, ng/mL 2.002 0.076–52.890 0.678
   Age, yr 0.943 0.895–0.993 0.025
   eGFR, mL/min/1.73 m2 0.969 0.948–0.990 0.005
   UACR, μg/mg 1.001 1.0002–1.0021 0.010
   UPCR, mg/mg × 100 1.001 1.0004–1.0021 0.03
   Glucose variability, CV% 1.094 1.011–1.184 0.026
   SBP, mmHg 1.041 1.002–1.080 0.037
   DBP, mmHg 1.074 1.013–1.138 0.016
   Hypertension, yes/no 8.214 1.736–38.860 0.008
   Use of ACE inhibitor, yes/no 6.000 1.773–20.305 0.004
   Use of β-blocker, yes/no 20.143 5.157–78.680 < 0.001
   Use of CCB, yes/no 4.317 1.290–14.442 0.018
   Use of diuretics, yes/no 16.111 2.839–91.440 0.002
   HDL-C 1.041 1.007–1.075 0.017
  Adjusted ORs
   Adiponectin, μg/mL 1.340 1.016–1.769 0.039
   Age, yr 0.824 0.666–1.020 0.076
   UACR, μg/mg 1.001 0.9997–1.002 0.131

Continuous variables (age, adiponectin, glypican-4, irisin, visfatin, eGFR, UACR, UPCR, glucose variability [CV%], SBP, DBP, HDL-C), categorical variables (hypertension, use of insulin, use of β-blocker, use of CCB, use of diuretics). Glucose variability (CV%) = SD/mean of fasting glucose variability × 100.

OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; UACR, urine albumin to creatinine ratio;UPCR, urine protein to creatinine ratio; CV, coefficient of variance; SBP, systolic blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; ACE, angiotensin converting enzyme; HDL-C, high density lipoprotein cholesterol.

Table 5.
Relative risks for microvascular complications in study cohort
Variable Case, n (%) OR 95% CI p value
Retinopathy 89 (55.6)
 Unadjusted ORs
  Adiponectin, μg/mL 1.037 0.953–1.127 0.400
  Glypican-4, ng/mL 0.994 0.980–1.009 0.464
  Irisin, μg/mL 0.578 0.369–0.905 0.017
  Visfatin, ng/mL 0.289 0.362–23.192 0.316
  eGFR, mL/min/1.73 m2 0.987 0.975–0.999 0.028
  Glucose variability, CV% 1.052 1.015–1.091 0.006
  Fasting plasma glucose, mg/dL 1.007 1.000–1.013 0.048
  Duration of DM, yr 1.101 1.044–1.161 < 0.001
  SBP, mmHg 1.027 1.005–1.049 0.016
  Hypertension, yes/no 3.063 1.567–5.987 0.001
  Use of sulfonylurea, yes/no 2.200 1.077–4.492 0.030
  Use of ACE inhibitor, yes/no 2.383 1.057–5.372 0.036
  Use of β-blocker, yes/no 10.909 1.383–86.066 0.023
  Use of CCB, yes/no 3.660 1.651–8.112 0.001
 Adjusted ORs
  Fasting plasma glucose, mg/dL 1.012 1.003–1.022 0.011
  Duration of DM, yr 1.081 1.020–1.145 0.008
  Hypertension, yes/no 2.722 1.224–6.054 0.014
  Use of sulfonylurea, yes/no 3.901 1.487–10.230 0.006
Neuropathy 64 (40.3)
 Unadjusted ORs
  Adiponectin, μg/mL 1.114 1.012–1.228 0.028
  Glypican-4, ng/mL 0.995 0.980–1.011 0.562
  Irisin, μg/mL 0.739 0.470–1.163 0.192
  Visfatin, ng/mL 1.008 0.122–8.310 0.994
  Age, yr 1.037 1.009–0.167 0.010
  eGFR, mL/min/1.73 m2 0.982 0.970–0.995 0.005
  Duration of DM, yr 1.131 1.071–1.194 < 0.001
  SBP, mmHg 1.033 1.010–1.056 0.004
  Hypertension, yes/no 2.340 1.219–4.490 0.011
  Use of insulin, yes/no 4.284 1.906–9.627 < 0.001
  Use of CCB, yes/no 3.099 1.502–6.395 0.002
  Hemoglobin, g/dL 0.771 0.615–0.966 0.024
 Adjusted ORs
  Hypertension, yes/no 2.452 1.063–5.659 0.036
  Duration of DM, yr 1.123 1.058–1.192 < 0.001
  Use of insulin, yes/no 4.211 1.641–10.807 0.003
  Hemoglobin, g/dL 0.801 0.611–1.050 0.108

Continuous variables (adiponectin, glypican-4, irisin, visfatin, eGFR, glucose variability, SBP, fasting plasma glucose, duration of DM, age, hemoglobin), categorical variables (hypertension, use of sulfonylurea, use of ACE inhibitor, use of β-blocker, use of CCB, use of insulin).

OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; CV, coefficient of variance; DM, diabetes mellitus; SBP, systolic blood pressure; ACE, angiotensin converting enzyme; CCB, calcium channel blocker.

Table 6.
Relative risks for macrovascular complications in study cohort
Variable Case, n (%) OR 95% CI p value
Cardiovascular disease 31 (19.4)
 Unadjusted ORs
  Adiponectin, μg/mL 1.002 0.909–1.104 0.966
  Glypican-4, ng/mL 1.002 0.984–1.021 0.809
  Irisin, μg/mL 0.662 0.352–1.247 0.202
  Visfatin, ng/mL 5.103 0.371–70.151 0.223
  Age, yr 1.047 1.009–1.085 0.013
  eGFR, mL/min/1.73 m2 0.987 0.973–1.001 0.067
  Duration of DM, yr 1.112 1.056–1.170 < 0.001
  Hypertension, yes/no 5.750 2.376–13.916 < 0.001
  Use of β-blocker, yes/no 5.979 1.847–19.359 0.003
  Use of CCB, yes/no 2.359 1.037–5.369 0.041
 Adjusted ORs
  Duration of DM, yr 1.107 1.049–1.168 < 0.001
  Hypertension, yes/no 5.041 1.951–13.024 0.001
Cerebrovascular disease 16 (10.0)
 Unadjusted ORs
  Adiponectin, μg/mL 3.044 0.543–17.053 0.205
  Glypican-4, ng/mL 1.004 0.980–1.027 0.769
  Irisin, μg/mL 1.096 0.565–2.126 0.787
  Visfatin, ng/mL 1.018 0.039–26.343 0.992
  Age, yr 1.036 0.989–1.085 0.132
  eGFR, mL/min/1.73 m2 0.984 0.966–1.003 0.091
  Glucose variability, CV% 1.062 1.012–1.115 0.015
  Duration of DM, yr 1.072 1.013–1.134 0.016
  Hypertension, yes/no 1.483 0.527–4.174 0.456
  Use of diuretics, yes/no 10.846 1.985–59.262 0.006
 Adjusted ORs
  Glucose variability, CV% 1.056 1.003–1.111 0.038
  Duration of DM, yr 1.067 1.004–1.134 0.038

Continuous variables (adiponectin, glypican-4, irisin, visfatin, age, eGFR, duration of DM, glucose variability [CV%]), categorical variables (hypertension, use of β-blocker, use of CCB, use of diuretics).

OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; DM, diabetes mellitus; CCB, calcium channel blocker; CV, coefficient of variance.


1. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–334.
crossref pmid
2. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006;55:774–779.
crossref pmid
3. Lafontan M. Adipose tissue and adipocyte dysregulation. Diabetes Metab 2014;40:16–28.
crossref pmid
4. Romacho T, Elsen M, Rohrborn D, Eckel J. Adipose tissue and its role in organ crosstalk. Acta Physiol (Oxf ) 2014;210:733–753.
crossref pmid
5. Mills KT, Hamm LL, Alper AB, et al. Circulating adipocytokines and chronic kidney disease. PLoS One 2013;8:e76902.
crossref pmid pmc
6. Adamczak M, Chudek J, Wiecek A. Adiponectin in patients with chronic kidney disease. Semin Dial 2009;22:391–395.
crossref pmid
7. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol 2013;305:F1629–F1636.
crossref pmid
8. Min HS, Kim JE, Lee MH, et al. Effects of Toll-like receptor antagonist 4,5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet. Kidney Res Clin Pract 2014;33:33–44.
crossref pmid pmc
9. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 2010;1212:E1–E19.
crossref pmid pmc
10. Cha JJ, Hyun YY, Jee YH, et al. Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Kidney Res Clin Pract 2012;31:177–185.
crossref pmid pmc
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553.
crossref pmid
12. Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann Intern Med 2016;164:542–552.
crossref pmid
13. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 2014;64:510–533.
crossref pmid
14. Guo X, Zhou G, Guo M, Cheung AK, Huang Y, Beddhu S. Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II. Physiol Rep 2014;2:e00230.

15. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008;74:649–654.
crossref pmid
16. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2599–2606.
crossref pmid
17. Looker HC, Krakoff J, Funahashi T, et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004;89:4010–4017.
crossref pmid
18. Martinez Cantarin MP, Keith SW, Waldman SA, Falkner B. Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrol Dial Transplant 2014;29:2268–2277.
crossref pmid pmc pdf
19. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129–134.
crossref pmid pdf
20. Martinez Cantarin MP, Waldman SA, Doria C, et al. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 2013;83:487–494.
crossref pmid pmc
21. Herder C, Bongaerts BW, Rathmann W, et al. Differential association between biomarkers of subclinical inflammation and painful polyneuropathy: results from the KORA F4 study. Diabetes Care 2015;38:91–96.
crossref pmid
22. Ussar S, Bezy O, Bluher M, Kahn CR. Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes 2012;61:2289–2298.
crossref pmid pmc
23. Yoo HJ, Hwang SY, Cho GJ, et al. Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2013;98:2897–2901.
crossref pmid pdf
24. Watanabe K, Yamada H, Yamaguchi Y. K-glypican: a novel GPI-anchored heparin sulfate proteoglycan that is highly expressed in developing brain and kidney. J Cell Biol 1995;130:1207–1218.
crossref pmid pmc
25. Strate I, Tessadori F, Bakkers J. Glypican4 promotes cardiac specification and differentiation by attenuating canonical Wnt and Bmp signaling. Development 2015;142:1767–1776.
crossref pmid
26. Chang GY, Park AS, Susztak K. Tracing the footsteps of glomerular insulin signaling in diabetic kidney disease. Kidney Int 2011;79:802–804.
crossref pmid pmc
27. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 2014;37:2359–2365.
crossref pmid
28. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000;23:45–50.
crossref pmid
29. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349–1354.
crossref pmid
30. Wu J, Bostrom P, Sparks LM, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012;150:366–376.
crossref pmid pmc
31. Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One 2013;8:e60563.

32. Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013;27:365–369.
crossref pmid
33. Liu JJ, Liu S, Wong MD, et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complications 2014;28:208–213.
crossref pmid
34. Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. Acta Physiol (Oxf ) 2015;213:711–721.
crossref pmid
35. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748–1758.
crossref pmid
36. Kang YS, Cha DR. The role of visfatin in diabetic nephropathy. Chonnam Med J 2011;47:139–143.
crossref pmid pmc
37. Vikram NK, Misra A, Pandey RM, et al. Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard. Diabetes Nutr Metab 2003;16:32–40.
38. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F, MMKD Study Group. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007;71:1279–1286.
crossref pmid
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6792   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
Copyright © 2019 The Korean Association of Internal Medicine. All rights reserved.
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
powerd by m2community